Comparing the performance of hybrid capture ii and polymerase chain reaction (PCR) for the identification of cervical dysplasia in the screening and diagnostic settings

Clinical Medicine Insights: Oncology

Volumn 7, Issue , 2013, Pages 247-255

  Luu, Hung N ^a,b   Adler Storthz, Karen ^c   Dillon, Laura M ^c   Follen, Michele ^d   Scheurer, Michael E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cervical dysplasia; Comparison; Hybrid capture II (HC II); Polymerase chain reaction (PCR); Test accuracy

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; FEMALE; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HUMAN; HUMAN TISSUE; HYBRID CAPTURE II; INTERMETHOD COMPARISON; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; WART VIRUS;

EID: 84884794374     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S12811     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
2. Pierce Campbell CM, Menezes LJ, Paskett ED, Giuliano AR. Prevention of invasive cervical cancer in the United States: past, present, and future. Cancer Epidemiology, Biomarkers & Prevention. 2012;21(9):1402-8.
3. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(3):368-83.
4. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management abnormal cervical cancer screening tests and cancer precursors. Obste Gynecol. 2013;121(4):829-46.
5. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(S3):78-89.
6. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, etal. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47(6):864-71.
7. Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study. Int J Cancer. 2008;122(10):2294-300.
8. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol. 2005;99(3S1):S7-11.
9. Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis Markers. 2007;23:273-81.
10. US Food and Drug Administration. 2003. Digene Hybrid Capture 2 High-Risk HPV DNA Test (Labeling). Accessed link: http://www.accessdata.fda.gov.www5.sph.uth.tmc.edu:2048/cdrh_docs/pdf/p890064s009a.pdf; Accessed date: 07/10/2013.
11. US Food and Drug Administration. 2011. COBAS HPV Test-P100020. Accessed link: http://www.fda.gov.www5.sph.uth.tmc.edu:2048/Medical Devices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm254518.htm; Accessed date: 07/10/2013.
12. US Food and Drug Administration. 2011. APTIMA® HPV Assay-P100042. Accessed link: http://www.fda.gov.www5.sph.uth.tmc.edu:2048/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm278520.htm; Accesed date: 07/10/2013.
13. Venturoli S, Cricca M, Bonvicini F, Giosa F, Pulvirenti FR, Galli C, et al. Human papillomavirus DNA testing by PCR-ELISA and hybrid capture II from a single cytological specimen: concordance and correlation with cytological results. J Clin Virol. 2002;25(2):177-85.
14. Castle PE, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, et al. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol. 2003;41(9):4022-30.
15. Kulmala SM, Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, etal. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol. 2004;42(6):2470-5.
16. Cuzick J, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol. 2010;82(7):1186-91.
17. Castle PE, Gutierrez EC, Leitch SV, Maus CE, McMillian RA, Nussbaumer WA, etal. Evaluation of a new DNA test for detection of carcinogenic human papillomavirus. J Clin Microbiol. 2011;49(8):3029-2.
18. Cardenas-Turanzas M, Nogueras-Gonzalez GM, Scheurer ME, Adler-Storthz K, Benedet JL, Beck JR, etal. The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2865-71.
19. Scheurer ME, Guillaud M, Tortolero-Luna G, McAulay C, Follen M, Adler-Storthz K. Human papillomavirus-related cellular changes measured by cytometric analysis of DNA ploidy and chromatin texture. Cytometry B Clin Cytom. 2007;72(5):324-31.
20. Guillaud M, Adler-Storthz K, Malpica A, Staerkel G, Matisic J, Van Niekirk D, etal. Subvisual chromatin changes in cervical epithelium measured by texture image analysis and correlated with HPV. Gynecol Oncol. 2005;99(3S1):S16-23.
21. Scheurer ME, Dillon LM, Chen Z, Follen M, Adler-Storthz K. Absoluate quantitative real-time polymerase chain reaction for the measurement of human papillomavirus E7mRNA in cervical cytobrush specimens. Infect Agent Cancer. 2007;2:8.
22. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker T, Wolinski SM. Use of the polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells. 1989;7:209-15.
23. Cubie HA, Seagar AL, McGoogan E, Whitehead J, Brass A, Arends MJ, et al. Rapid real time PCR to distinguish between high risk human papillomavirus types 16 and 18. Mol Pathol. 2001;54(1):24-9.
24. Szuhai K, Sandhaus E, Kolkman-Uljee SM, Lemaître M, Truffert JC, Dirks RW, etal. A novel strategy for human papillomavirus detection and genotyping with SybrGreen and molecular beacon polymerase chain reaction. Am J Pathol. 2001;159(5):1651-60.
25. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-9.
26. Rosner B. Fundamentals of biostatistics. 7th ed. Boston, MA: Brooks/Cole, Cengage Learning; 2011.
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74.
28. Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE, Alts G. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am J Clin Pathol. 2005;124(5):722-32.
29. Castanon A, Ferryman S, Patnick J, Sasieni P. Review of cytology and histopathology as part of the NHS Cervical Screening Program audit of invasive cervical cancers. Cytopathology. 2011;23(1):13-22.
30. Giovannelli L, Lama A, Capra G, Giordano V, Arico P, Ammatuna P. Detection of human papillomavirus DNA in cervical samples: analysis of the new PGMY-PCR compared to the hybrid capture II and MY-PCR assays and a two-step nested PCR assay. J Clin Microbiol. 2004;42(8):3861-4.
31. Castle PE, Solomon D, Hildesheim A, Herrero R, Concepcion Bratti M, Sherman ME, etal. Stability of archived liquid-based cervical cytologic specimens. Cancer. 2003;99(2):89-96.